University of Helsinki
helsinki.fiTotal trials
132
Active
21
Phase 3
7
Total enrollment
326,899
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Biomolecular profiling | — | — | — | — | — | 1 |
Next readouts
- 2027-12-31
Top conditions
- Colorectal Cancer3
- Language Development3
- Atherosclerosis3
- Cardiovascular Diseases3
- BPH (Benign Prostatic Hyperplasia)3
- Periodontitis3
- Serum 25-hydroxyvitamin D Concentrations (25OHD)2
- Coronary Artery Disease2
Frequently asked questions about University of Helsinki
- How many clinical trials does University of Helsinki have on ClinicalTrials.gov?
- University of Helsinki is listed as the lead sponsor on 132 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Helsinki's trials are in Phase 3?
- 7 of University of Helsinki's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does University of Helsinki focus on?
- University of Helsinki's most-studied conditions on ClinicalTrials.gov are Colorectal Cancer, Language Development, Atherosclerosis, Cardiovascular Diseases, BPH (Benign Prostatic Hyperplasia).
- When are University of Helsinki's next clinical trial readouts?
- University of Helsinki has 1 upcoming primary-completion readout tracked here; the soonest is “Systems Oncology Approach to Optimize Ovarian Cancer Treatment”, expected around 2027-12-31.